Correlation between the treated volume, the GTV and the CTV at the time of brachytherapy and the histopathologic findings in 33 patients with operable cervix carcinoma
- PMID: 15542166
- DOI: 10.1016/j.radonc.2004.07.028
Correlation between the treated volume, the GTV and the CTV at the time of brachytherapy and the histopathologic findings in 33 patients with operable cervix carcinoma
Abstract
Background and purpose: This study correlates the treated volume, the GTV and the CTV at the time of intracavitary brachytherapy (BT) with the histopathological findings obtained by surgery (S) in 33 patients (pts) with cervix carcinoma.
Patients and methods: Sixteen pts (group I), FIGO stage IB1 (1), IB2 (4), IIB (10), IIIB (1), received external beam radiotherapy (EBT) with a total dose of 45 Gy in 5 weeks and concomitant CISPLATIN 40 mg/m(2) weekly, followed by BT up to a total dose of 15 Gy. S was performed 6-8 weeks thereafter. Seventeen pts (group II), FIGO IA2 (1), IB1 (14), IIB (2), were treated by BT alone with a total dose of 60 Gy and S after 6-8 weeks. All pts had a MRI examination after BT with a moulded applicator in situ for exact delineation of GTV, CTV and critical organs and a 3D dosimetry directly from MRI data.
Results: In group I (EBT + BT + S), the histopathological findings showed complete tumour sterilization (CR) in 56% of pts. Residual disease (RD) was found in 43%. Dosimetric data showed in pts with CR a larger mean treated volume (213 vs. 166 cm(3)) and a better mean coverage of the GTV and the CTV by the reference isodose (99 and 91%) as in pts with RD (85 and 77%). In group II (BT + S), CR was found in 52%, RD in 41%. Dosimetric data showed a larger mean treated volume (154 vs. 109 cm(3)) for pts with RD and a mean coverage of the GTV and the CTV by the reference isodose of 97 and 84% vs. 89 and 80% for pts with CR.
Conclusions: An incomplete coverage of the GTV and/or the CTV by the reference isodose is an important risk factor for RD at the time of surgery. Furthermore, for pts who received BT alone, tumour size seemed to be a limiting factor for an accurate coverage of the CTV by the reference isodose.
Comment in
-
Comment on "Correlation between the treated volume, the GTV and the CTV at the time of brachytherapy and histopathologic findings in 33 patients with operable cervix carcinoma".Radiother Oncol. 2005 Jun;75(3):367-8; author reply 368-9. doi: 10.1016/j.radonc.2005.03.018. Radiother Oncol. 2005. PMID: 15885824 No abstract available.
Similar articles
-
[Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].Cancer Radiother. 2004 Jun;8(3):168-77. doi: 10.1016/j.canrad.2004.02.002. Cancer Radiother. 2004. PMID: 15217584 Clinical Trial. French.
-
Pilot study in the treatment of endometrial carcinoma with 3D image-based high-dose-rate brachytherapy using modified Heyman packing: clinical experience and dose-volume histogram analysis.Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):468-78. doi: 10.1016/j.ijrobp.2004.10.013. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890589 Review.
-
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.Radiother Oncol. 2005 Mar;74(3):235-45. doi: 10.1016/j.radonc.2004.12.015. Radiother Oncol. 2005. PMID: 15763303 Review.
-
Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix.Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1157-64. doi: 10.1016/j.ijrobp.2008.09.010. Epub 2008 Dec 26. Int J Radiat Oncol Biol Phys. 2009. PMID: 19101097
-
DVH parameters and outcome for patients with early-stage cervical cancer treated with preoperative MRI-based low dose rate brachytherapy followed by surgery.Radiother Oncol. 2009 Nov;93(2):316-21. doi: 10.1016/j.radonc.2009.05.004. Epub 2009 Jul 6. Radiother Oncol. 2009. PMID: 19586673
Cited by
-
MRI-based pre-planning in patients with cervical cancer treated with three-dimensional brachytherapy.Br J Radiol. 2011 Sep;84(1005):850-6. doi: 10.1259/bjr/75446993. Br J Radiol. 2011. PMID: 21849368 Free PMC article.
-
Aiming for 100% Local Control in Locally Advanced Cervical Cancer: The Role of Complex Brachytherapy Applicators and Intraprocedural Imaging.Semin Radiat Oncol. 2020 Oct;30(4):300-310. doi: 10.1016/j.semradonc.2020.05.002. Semin Radiat Oncol. 2020. PMID: 32828386 Free PMC article. Review.
-
Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study.Radiat Oncol. 2006 May 4;1:13. doi: 10.1186/1748-717X-1-13. Radiat Oncol. 2006. PMID: 16722546 Free PMC article.
-
Pathologic complete remission after preoperative high-dose-rate brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized multicenter study.Pathol Oncol Res. 2015 Apr;21(2):247-56. doi: 10.1007/s12253-014-9815-5. Epub 2014 Jul 11. Pathol Oncol Res. 2015. PMID: 25011515 Clinical Trial.
-
Dosimetric research into target regions and organs at risk in three-dimensional intracavitary brachytherapy techniques for Chinese patients with cervical carcinoma.J Radiat Res. 2019 Jan 1;60(1):124-133. doi: 10.1093/jrr/rry088. J Radiat Res. 2019. PMID: 30452658 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous